$ABCL
AbCellera Biologics Inc. Common Shares
XNAS•Health Care•Pharmaceutical Preparations
$13.75
▼-1.15%-$0.160
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateAbCellera Biologics Inc. Common Shares
XNAS•Health Care•Pharmaceutical Preparations
Why is ABCL down today? It is at $13.75 (-1.15%), and our scanner flagged it 194 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ABCL spikes, and full due diligence on ABCL — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $ABCL 194 times in the last 30 days. Create a free account to track $ABCL, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on ABCL from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ABCL today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystPriced share offering, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Aug 24, 2026 · 40 days agoAcross every filing on file, supply equal to 20.7% of the tradeable float is in play - 20.7% has already been sold.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
20,512,823 new shares · About $187.0M in size · Priced at $9.75/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Hayden Michael R Director | Bought (open market) | +54K 0.02% of company | added 3.7% | 1.49M | $570K at $10.64 | Aug 24, 26 |
Montalbano John S. Director | Bought (open market) | +10K | added 4.1% | 251K | $110K at $11.03 | Aug 18, 26 |
Booth Andrew Officer | Bought (open market) | +37K 0.01% of company | added 8.3% | 483K | $384K at $10.32 | Aug 14, 26 |
Hayden Michael R Director | Bought (open market) | +46K 0.02% of company | added 3.3% | 1.44M | $481K at $10.37 | Aug 12, 26 |
Hayden Michael R Director | Sold (automatic/other) | -50K 0.02% of company | sold 3.5% | 1.39M | n/a | Aug 11, 26 |
Booth Andrew Officer | Other | 250K 0.08% of company | added 100% | 446K | $48K at $0.190 | Jun 3, 26 |
Montalbano John S. Director | Bought (open market) | +20K | added 9.0% | 241K | $95K at $4.77 | May 14, 26 |
Booth Andrew Officer | Bought (open market) | +43K 0.01% of company | added 28% | 196K | $146K at $3.42 | Feb 27, 26 |
Thermopylae Holdings Ltd. Beneficial Owner (10%) | Bought (open market) | +38K 0.01% of company | added <0.1% | 56.13M | $131K at $3.44 | Feb 27, 26 |
Thermopylae Holdings Ltd. Beneficial Owner (10%) | Bought (open market) | +177K 0.06% of company | added 0.3% | 56.10M | $580K at $3.27 | Feb 26, 26 |
Thermopylae Holdings Ltd. Beneficial Owner (10%) | Sold (automatic/other) | -225K 0.07% of company | sold 0.4% | 55.92M | n/a | Dec 18, 25 |
Montalbano John S. Director | Bought (open market) | +50K 0.02% of company | added 29% | 221K | $179K at $3.57 | Nov 26, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on ABCL from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ABCL today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
ABCL last traded at $13.75, down 1.15% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
AbCellera Biologics Inc. Common Shares (ABCL) is next expected to report earnings on Thursday, November 5, 2026, about 32 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The ABCL Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ABCL 194 times in the last 30 days.
ABCL (AbCellera Biologics Inc. Common Shares) trades on XNAS, with a market cap of about $4.45B in the PHARMACEUTICAL PREPARATIONS sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ABCL for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$ABCL discussion
Sign in to ask a question or join the discussion.